CSL Behring reaffirms unwavering commitment to Chinese patients

Australia-based global biotherapeutics company CSL Behring has reaffirmed its commitment to the core value of "Patient Focus" and delivering innovative therapies to Chinese patients by leveraging its scientific expertise, local collaborations and advanced technology. Its parent company, CSL, with a history of over 100 years, now employs more than 32,000 people and delivers its lifesaving therapies to people in more than 100 countries.

"Patient focus is our unwavering promise, rooted in who we are and what we do. This is why we are here in China," said Cissy Wang, general manager of CSL Behring China. "Since introducing human albumin to China in 1986, CSL Behring has become a leading supplier of lifesaving treatments for millions of patients with life-threatening medical conditions."

"Human albumin is a strategic priority product for us in China," Wang said. As a leader in the albumin therapeutics industry in China, CSL Behring is committed to leveraging its extensive multidisciplinary clinical expertise and collaborating with stakeholders to promote the rational use of albumin, deepen its clinical value, drive industry advancement, and ultimately improve the quality of life for Chinese patients with serious diseases.

CSL Behring has built a robust global research and development pipeline by leveraging three strategic scientific platforms: Plasma Fractionation, Recombinant Protein Technology, and Cell and Gene Therapy. With the global company ambition "to deliver enduring patient impact in areas of high unmet medical need", CSL Behring continues to discover, develop and deliver innovative therapies for people living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant areas.

"As the world's second-largest pharmaceutical market and a premier innovation hub, China constitutes an indispensable component of multinational pharmaceutical companies' global health strategies," Wang said. "China's people-centered development philosophy aligns with CSL Behring's core value of 'Patient Focus' and our mission to save lives and help people lead fuller lives."

Meanwhile, CSL Behring has deepened its presence in China through proactive policy engagement, distribution partnerships and R&D collaborations. Aligning with national policies that establish special access channels for critical medications unavailable domestically, under the Guangdong-Hong Kong-Macao Greater Bay Area's special access policy for Hong Kong and Macao drugs and medical devices, CSL Behring introduced clinically critical therapies at the University of Hong Kong-Shenzhen Hospital and the First Affiliated Hospital, Sun Yat-sen University, which has benefited around 2,800 "panda blood "pregnant women in China by now.

Wang pointed out that it's crucial to collaborate with partners in China to expand distribution and drive innovation. This year, CSL Behring renewed its fourth-party logistics agreement with Sinopharm Group to enhance supply chain efficiency for imported albumin and specialty therapies. In March, Paul McKenzie, CEO and managing director of CSL, met with key opinion leaders from Peking Union Medical College Hospital and Shanghai Ruijin Hospital to explore potential opportunities for scientific research collaboration.

Considering the opportunities and challenges, CSL Behring will continue to strengthen its innovative product portfolio in China while advocating for the clinical value of albumin.

For future growth, Wang said that CSL Behring has established the 3N Strategy as its framework for advancing three priority areas: New Products to benefit more patients, New Collaborations with various stakeholders to build a sustainable industry ecosystem, and New Efficiency driven by internal and external factors to take a lead in the industry.

New Efficiency, for instance, involves accelerating the integration of artificial intelligence to revolutionize healthcare delivery in China. CSL Behring Medical Chatbot, an AI-powered, evidence-based medical knowledge platform for albumin therapeutics, is currently undergoing pilot testing. This system significantly optimizes medical communication with healthcare professionals and is poised for broad implementation.

While recognizing AI's potential to enhance efficiency, the company continuously invests in empowering its employees to identify critical issues and frame the right questions to maximize AI's value.

CSL Behring will celebrate its 40th anniversary in China in 2026. "We are committed to enhancing the consistency of quality and the reliability of supply to improve patient accessibility in China, and we will continue to accelerate the introduction of clinically critical and innovative therapies to the country," Wang said.